DE3684825D1 - Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. - Google Patents

Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Info

Publication number
DE3684825D1
DE3684825D1 DE8686401442T DE3684825T DE3684825D1 DE 3684825 D1 DE3684825 D1 DE 3684825D1 DE 8686401442 T DE8686401442 T DE 8686401442T DE 3684825 T DE3684825 T DE 3684825T DE 3684825 D1 DE3684825 D1 DE 3684825D1
Authority
DE
Germany
Prior art keywords
pyrrolidinylmethyl
allyl
methoxy
disease
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8686401442T
Other languages
English (en)
Inventor
Denis Dr Besancon
Brenda Dr Costall
Robert J Dr Naylor
Peter Dr Jenner
Charles D Prof Marsden
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE PARIS FR Ste
Original Assignee
D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE PARIS FR Ste
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE PARIS FR Ste filed Critical D'ETUDES SCIENTIFIQUES ET INDUSTRIELLES DE L'ILE-DE-FRANCE PARIS FR Ste
Application granted granted Critical
Publication of DE3684825D1 publication Critical patent/DE3684825D1/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrrole Compounds (AREA)
DE8686401442T 1985-07-15 1986-06-30 Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit. Expired - Fee Related DE3684825D1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8510802A FR2584605B1 (fr) 1985-07-15 1985-07-15 Application du n-(1-allyl-2-pyrrolidinylmethyl) 2-methoxy 4-amino 5-methylsulfamoyl benzamide dans le traitement de la maladie de parkinson

Publications (1)

Publication Number Publication Date
DE3684825D1 true DE3684825D1 (de) 1992-05-21

Family

ID=9321301

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8686401442T Expired - Fee Related DE3684825D1 (de) 1985-07-15 1986-06-30 Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.

Country Status (6)

Country Link
US (1) US4725618A (de)
EP (1) EP0210099B1 (de)
JP (1) JPS6219518A (de)
AT (1) ATE74755T1 (de)
DE (1) DE3684825D1 (de)
FR (1) FR2584605B1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002028882A1 (en) * 2000-10-06 2002-04-11 Xenoport, Inc. Bile acid prodrugs of l-dopa and their use in the sustained treatment of parkinsonism

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3342826A (en) * 1964-01-13 1967-09-19 Ile De France Heterocyclic aminoalkyl benzamides
FR2358892A1 (fr) * 1976-07-19 1978-02-17 Ile De France N(1'-allyl 2'-pyrrolidylmethyl)2,3-dimethoxy 5-sulfamoyl benzamide, ses derives
US4263316A (en) * 1978-10-11 1981-04-21 Societe D'etudes Scientifiques Et Industrielles De L'ile De France N-(1-Methyl-2-pyrrolidinylmethyl)-2,3-dimethoxy-5-methylsulfamoyl benzamide and its derivatives, methods of preparing them and their application to the treatment of troubles of the lower part of the body
FR2489327B1 (fr) * 1980-08-28 1984-05-18 Ile De France N (1 allyl 2 pyrrolidinyl methyl) 2 methoxy 4 amino 5 methylsulfa moyl benzamide, son procede de preparation et son application comme medicament

Also Published As

Publication number Publication date
EP0210099A3 (en) 1989-11-23
EP0210099B1 (de) 1992-04-15
EP0210099A2 (de) 1987-01-28
JPS6219518A (ja) 1987-01-28
ATE74755T1 (de) 1992-05-15
US4725618A (en) 1988-02-16
FR2584605B1 (fr) 1988-06-17
FR2584605A1 (fr) 1987-01-16

Similar Documents

Publication Publication Date Title
ATE225176T1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
DE10199020I1 (de) Galanthamin oder dessen Analoge zur Behandlung der Alzheimerschen Krankheit
ATE411026T1 (de) Mittel zur behandlung der alzheimer-krankheit
DK130387D0 (da) Transglutaminase inhibitorer
DE3683318D1 (de) Verwendung von alfuzosin zur behandlung von erkrankungen der harnwege.
ES2063060T3 (es) Benzamida contra enfermedades cognoscitivas.
DE3883606D1 (de) Verwendung von Fluoxetin zur Behandlung des Diabetes.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
ATE106736T1 (de) Verwendung von dimethylpolysiloxan zur behandlung von erkrankungen des gastrointestinaltraktes.
DE3854121T2 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
FI864570A0 (fi) Terapeutiskt anvaendbar foerening.
ATE107859T1 (de) Verwendung von antiprogestomimetika zur stimulierung des eisprungs.
ATE222491T1 (de) Melatonin-derivate zur verwendung in der behandlung von schlafstörungen
DE3680507D1 (de) Verwendung von oxirancarbonsaeuren zur behandlung der hyperlipaemie.
ATE25969T1 (de) 1,7-diphenyl-3-methylaza-7-cyan-8-methyl-nonan zur verwendung bei der bekaempfung von krankheiten.
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE3686688T2 (de) Verwendung von sulfanilamido quinoxalinen zur behandlung von neoplastischen krankheiten.
DE59101581D1 (de) Verwendung von efeu zur topischen behandlung der psoriasis.
ATE143058T1 (de) Typisierung humaner rhinoviren
DE3671698D1 (de) Anordnung zur stimulation von akupunkturpunkten.
DE3772764D1 (de) Anwendung von n-((1-aethyl-2-pyrrolidinyl)methyl)-methoxy-5-sulfamoylbenzamid zur sterilitaetsbehandlung.
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.
DE3683330D1 (de) Verwendung von imidazolinylaminoisoindolen und verwandten verbindungen zur behandlung von hyperglykaemie.
ATE59106T1 (de) Anordnung zur behandlung von bildern.
ATE53291T1 (de) Anordnung zur stimulation von akupunkturpunkten.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee